News from circassia ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 01, 2013, 04:00 ET Circassia's Rapid Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

OXFORD, England, Oct. 1, 2013 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II...


Sep 12, 2013, 04:00 ET Circassia's Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction

OXFORD, England, Sept. 12, 2013 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust...


Sep 27, 2012, 04:00 ET Circassia Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology

- Rapid four-dose regimen maintains significant symptom reduction one year after start of treatment - OXFORD, England, Sept. 27, 2012 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company...


Sep 18, 2012, 04:00 ET Circassia Appoints Stewart Sharpe as Vice President Commercial Operations

Newly-Created Position to Lead Commercialisation Preparations for Lead Allergy Programme OXFORD, England, Sept. 18, 2012 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on...


Sep 11, 2012, 04:00 ET Circassia Appoints Dr Brett Haumann as Chief Medical Officer

OXFORD, England, Sept. 11, 2012 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr...


Mar 08, 2012, 04:00 ET Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results

Results Presented at 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology OXFORD, England, March 8, 2012 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused...


Nov 18, 2010, 05:00 ET Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite
in Phase II Clinical Study of Novel T-cell Vaccine

OXFORD, England, Nov. 18 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine...


Sep 30, 2010, 05:00 ET Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy
Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine

Extended Clinical Portfolio Now Includes Four Mid-Stage Development Programmes OXFORD, England, Sept. 30 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today...


Feb 12, 2010, 04:00 ET Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy
T-Cell Vaccine

Results Mark Third Successful Phase II Study With ToleroMune(R) T-Cell Vaccines OXFORD, England, Feb. 12 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today...


Jan 19, 2010, 05:25 ET Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell
Vaccines Against House Dust Mite and Cat Allergies

OXFORD, England, Jan. 19 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines...


Dec 11, 2009, 04:00 ET Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment
Round

- Investment Follows Successful Phase II Clinical Results With cat Allergy T-cell Vaccine - Funding to Progress ToleroMune(R) T-cell Allergy Vaccines Into Late-Stage Development OXFORD, England, Dec. ...


Nov 20, 2009, 04:00 ET Circassia Announces Successful Results From Phase II Clinical Study of
ToleroMune(R) Cat Allergy Therapy

Study Identifies Optimal Treatment Approach for Late-Stage Development OXFORD, England, Nov. 20 /CNW/ - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced...